Form 4: Catalyst Pharma Director Exercises Options, Sells Shares

A director at Catalyst Pharmaceuticals, David S. Tierney, exercised stock options and subsequently sold a portion of the acquired shares to cover costs and taxes.

Summary

• Director David S. Tierney exercised options to acquire 50,000 shares of Catalyst Pharmaceuticals, Inc. common stock at an exercise price of $2.24 per share on August 27, 2025.
• Following the option exercise, Mr. Tierney beneficially owned 405,620 shares of common stock.
• On the same date, Mr. Tierney sold 26,000 shares of common stock on the open market at a weighted average price of $20.20 per share, with sales ranging from $20.10 to $20.32 per share.
• The sale was conducted to fund the exercise price of the options and cover estimated taxes due from the reporting person.
• After these transactions, Mr. Tierney's direct beneficial ownership of common stock is 379,620 shares.
• He also retains 158,274 options to purchase common stock.

Sentiment

Score: 4

Explanation: While the option exercise shows prior confidence and a significant gain for the director, the subsequent sale of shares, even for tax purposes, is generally viewed with slight caution by the market as it reduces insider ownership.

Positives

• Director David S. Tierney exercised options at a significantly lower price ($2.24) compared to the market sale price ($20.20), indicating a substantial in-the-money value for the options.
• The exercise of options demonstrates a prior long-term incentive alignment with the company's performance.

Negatives

• A director sold 26,000 shares of common stock, which, while stated to cover exercise costs and taxes, still represents a reduction in direct insider ownership.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The exercise of stock options and subsequent sale of shares by Director David S. Tierney constitutes a related party transaction as it involves a company insider.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares, even for tax purposes, as a slight reduction in insider confidence or commitment, potentially leading to minor negative sentiment.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors beyond potential market sentiment shifts.

Key Dates

Recommendation

The transaction involves a director exercising options and selling a portion of the shares to cover costs and taxes. While the sale reduces insider ownership, it's a common practice for option exercises and doesn't necessarily signal a lack of confidence in the company's long-term prospects. The significant gain from the option exercise ($2.24 exercise price vs. $20.20 sale price) highlights past positive performance. Without further information on the company's fundamentals or strategic direction, a 'hold' recommendation is appropriate, acknowledging the routine nature of such transactions while noting the slight reduction in insider stake.

Keywords

Catalyst Pharmaceuticals, CPRX, Insider Trading, Form 4, Stock Options, Director Transaction, Share Sale, David S. Tierney, Biotechnology, Pharmaceuticals